Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that it ranked number 4 in the 2021 Deloitte UK Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over the last four years. Touchlight grew 11,421 per cent during this period.
Touchlight’s Executive Chairman, Jonny Ohlson, said: “This recognition is a confirmation of our vision that DNA will underpin the future of healthcare. Our technology allows faster, smoother and more reliable development of genetic medicines. It is a category that had not been widely known until recently but which has underpinned a major leap forward in medicine development. Cell- and gene therapies, mRNA and DNA vaccines all rely on DNA, and we believe that Touchlight’s dbDNA will become a core component for such advanced therapies, transforming lives and patient access.”
Duncan Down, lead partner for the Deloitte UK Technology Fast 50 programme, said: “The extraordinary growth of this year’s Fast 50 represents the remarkable tenacity of the UK’s technology industry. Deloitte’s 2021 Fast 50 awards are a clear demonstration of the wealth of talent, creativity, and entrepreneurship in the UK’s technology industry today.
“The 50 fastest growing UK technology companies, as ranked by Deloitte, generated around £2.92bn in total annual revenues in the year 2020/21 and employed more than 19,320 people. The Deloitte UK Technology Fast 50 recorded an average three-year growth rate of 3,337 per cent.”
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as doggybone DNA” or dbDNA™.
dbDNA is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Karen Fallen, Chief Executive Officer||Agnes Stephens|
|Robin Bodicoat, Head of Marketing||E: firstname.lastname@example.org|
|E: email@example.com||T: +44 20 7457 2020|
|T: +44 20 8481 9200|